Images

Filter by

Figure 1 Timeline of Randomised Clinical Trials of Glucagon like Peptide 1 Receptor Agonists
Figure 1: Timeline of Randomised Clinical Trials of Glucagon-like Peptide-1 Receptor Agonists
Figure 2 Forest Plot Illustrating Significantly Independent in Hospital AllCause Mortality Predictors in the HK Cohort
Figure 2: Forest Plot Illustrating Significantly Independent in-Hospital AllCause Mortality Predictors in the HK Cohort
Table 2 Medication Use on Admission and Discharge in HK and Non HK Cohorts
Table 2: Medication Use on Admission and Discharge in HK and Non-HK Cohorts
Table 1 Demographics Comorbidities and In hospital Outcome During ADHF Admission in HK and Non HK Cohorts
Table 1: Demographics, Comorbidities and In-hospital Outcome During ADHF Admission in HK and Non-HK Cohorts
Figure 1 Flow Chart of the Study Population
Figure 1: Flow Chart of the Study Population
Table 2 Studies Investigating the Effect of risk factor modification on AF Ablation Outcome
Table 2: Studies Investigating the Effect of risk factor modification on AF Ablation Outcome
Table 1 Studies Investigating the Effect of Weight Reduction on AF Ablation Outcome
Table 1: Studies Investigating the Effect of Weight Reduction on AF Ablation Outcome
Figure 3 Cardiac MRI Showing Epicardial Adipose Tissue
Figure 3: Cardiac MRI Showing Epicardial Adipose Tissue
Figure 2 Left Atrial Strain
Figure 2: Left Atrial Strain
Figure 1 Obesity as an Independent Risk Factor in Promoting AF
Figure 1: Obesity as an Independent Risk Factor in Promoting AF
Central Illustration Flow Chart Summarising the Approach to a Patient with AF and Obesity with Focus on the Structured Weight Loss Programmes European Society of Cardiology ABC Approach
Central Illustration: Flow Chart Summarising the Approach to a Patient with AF and Obesity, with Focus on the Structured Weight Loss Programmes (European Society of Cardiology ABC Approach)
Figure 3 Guideline Recommendations for the Use of Sodium–Glucose Co transporter Inhibitors and Glucagon like Peptide 1 Receptor Agonists in HF
Figure 3: Guideline Recommendations for the Use of Sodium–Glucose Co-transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in HF